Human Genetic Engineering Final Project By: Jazmine Byrd … Continue reading →

Genetic Engineering and Insulin CSE 684 Assignment #3. By: Amanda Tuss … Continue reading →

An overview of Genetic Engineering 2 Genetic Engineering 2 -- better workflows, more productive post. By: QuantelOnline … Continue reading →

Genetic engineering and transgenic organisms By: JCauthers … Continue reading →

TTA14-OGM-Genetic Engineering TTA14-OGM-Genetic Engineering. By: Sallie Hill Outten … Continue reading →

John Sterling | 05/01/2014 The following article, reproduced in full below, was originally published at Genetic Engineering & Biotechnology News. Its been a hot year for biotech! As G. Steven Burrill, CEO of Burrill & Co., noted in a recent report, life science firms raised $2.9 billion in new equity capital globally from public investors in February. This included $1.1 billion raised by 18 companies that completed initial public offerings and $1.8 billion raised by 23 companies that completed follow-on offerings during the month. In the U.S., 16 life sciences companies raised $959 million through IPOs and 22 companies raised $1.75 billion through follow-on offerings on U.S. exchanges during February, making the month the biggest for IPOs in terms of the number of completed deals since February 2000! Why the excitement? Promising new biotherapeutics are emerging from the drug pipeline. Advances in stem cell research and regenerative medicine are occurring at a rapid pace. And OMICS technologies (e.g., genomics, proteomics, metabolomics, transcriptomics, glycomics, and lipomics), originally developed and used in the lab, are now making their way into clinical medicine, truly ready to usher in an era of personalized medicine. The 2014 BIO International Convention will be held in San … Continue reading →

Today virtually everything we eat is produced from seeds that have been genetically altered in some way. New methods of plant tinkering have emerged over the generations and so, too, have the fears Today virtually everything we eat is produced from seeds that have been genetically altered in one way or another. Credit: Thinkstock Editor's note: The following is the introduction to the May 2014 issue of Scientific American Classics: The Birth of the Great GMO Debate. The idea of intentionally infecting a plant with a bacterium might seem strange. Just three decades ago, however, researchers discovered that they could use this infection to deliver new and potentially useful genes into crops. What has long appeared to be simply the agent of a bothersome plant disease is likely to become a major tool for the genetic manipulation of plants: for putting new genes into plants and thereby giving rise to new varieties with desired traits, announced acclaimed scientist Mary-Dell Chilton in 1983 in a pioneering article, one of many in this collection from the archives of Scientific American. Today genes introduced this way are yielding some of the most exciting new approaches to food securityas well as a hearty amount … Continue reading →